Advancing Healthcare Naturally

Our products are manufactured in Lappeenranta, Finland. Since we launched GrowDex® in 2014, we have continued developing our nanocellulose product portfolio together with leading researchers and clinicians in their respective fields. Our current portfolio is centered around four main product categories.

Our future vision for regenerative medicine

We aim to provide Nanocellulose as a living cell carrier from source through the cell manufacturing all the way to the cell therapy treatment administered to a patient.

New modalities are gaining attention across the biotech and pharma field. However, a non-animal carrier is required for their successful registration with EMA/FDA. Our nanocellulose hydrogel not only suits the cell differention, manufacturing and purification, but also transportation of the ATMP product to the medical center without the need of freeze cycle. Finally, the application to a patient is possible in different forms: as an injection, as an implant, as topical treatment on a wound dressing, and as a freeze-dried product.

UPM has been the forerunner in nanocellulose research for decades. We pioneered the field together with academic and research centers in Finland and developed the manufacturing into an industrial scale at medical quality.

We have more than 150 optimized protocols for different cell types, more than 200 scientific publications including in vitro, in vivo and clinical studies.

Resource center